Compound: pravastatin
SMILES: O=C(O[C@@H]1[C@H]2C(C=C[C@@H]([C@@H]2CC[C@@H](O)C[C@@H](O)CC(=O)O)C)=C[C@H](C1)O)[C@H](CC)C
InChIKey: TUZYXOIXSAXUGO-PZAWKZKUSA-N
Synonyms: pravastatin, 81093-37-0, Pravastatina, Pravastatine, Pravastatinum, Eptastatin, Pravator, Pravastatinum [Latin], KXO2KT9N0G, (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid, C10AA03, DTXSID6023498, CHEBI:63618, Pravastatinum (Latin), 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-((2S)-2-methyl-1-oxobutoxy)-, (betaR,deltaR,1S,2S,6S,8S,8aR)-, 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betas*,deltas*),2alpha,6alpha,8beta(R*),8aalpha))-, (+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid, Apo Pravastatin, Lin Pravastatin, Nu Pravastatin, (+)-(3R,5R)-3,5-dihydroxy-7-((1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-(((S)-2-methylbutyryl)oxy)-1,2,6,7,8,8a-hexahydro-1-naphthyl)heptanoic acid, (3R,5R)-7-((1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-((2S)-2-methylbutanoyl)oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)-3,5-dihydroxyheptanoic acid, RefChem:56363, DTXCID003498, RMS431, Pravastatin tert Octylamine Salt, RMS 431, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1,2,6,7,8,8a-Hexahydro-beta,!d,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic Acid, Pravastatin acid, Pravachol, Pravastatin (INN), CHEMBL1144, (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid, (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid, (betaR,deltaR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-beta,delta,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-1-naphthaleneheptanoic acid, Pravastatine [French], Pravastatina [Spanish], Mevalothin, PRAVASTATIN [INN], Pravastatin [INN:BAN], Pravator (TN), (3R,5R)-3,5-Dihydroxy-7-((1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-(((S)-2-methylbutanoyl)oxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoic acid, CCRIS 7557, 3beta-Hydroxycompactin, C23H36O7, UNII-KXO2KT9N0G, Pravastatin-3H, KS-5015, PRAVASTATIN [VANDF], SCHEMBL1117, PRAVASTATIN [WHO-DD], BIDD:GT0773, PRAVASTATIN [EMA EPAR], GTPL2953, orb1704797, BDBM20688, HSDB 8368, TUZYXOIXSAXUGO-PZAWKZKUSA-N, HMS3715P11, HY-B0165, EBC-27049, LMFA05000695, MFCD00869375, s5713, AKOS015895229, CCG-221195, DB00175, NCGC00188962-01, NCGC00188962-02, (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxy-heptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid, FP158560, NS00000420, C01844, D08410, H12037, EN300-6481366, SR-01000781259, Q1240093, SR-01000781259-2, BRD-K60511616-236-01-4, BRD-K60511616-236-02-2, BRD-K60511616-236-06-3, BRD-K60511616-236-08-9, (|_R,|_R,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-|_,|_,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-1-naphthaleneheptanoic acid, (|AR,|AR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-|A,|A,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-1-naphthaleneheptanoic acid, 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-.beta.,.delta.,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (.beta.R,.delta,R,1S,2S,6S,8S,8aR)-
Theoretical properties:
molecular_formula: C23H36O7
molecular_weight: 424.5 g/mol
exact_mass: 424.24610348 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 4
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 11
heavy_atom_count: 30
topological_polar_surface_area: 124 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
boiling_point: >600 ºC at 760 mmHg
Descriptions:
{"pubchem": "Pravastatin is a carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin. It has a role as a metabolite, a xenobiotic, an anticholesteremic drug and an environmental contaminant. It is a carboxylic ester, a secondary alcohol, a hydroxy monocarboxylic acid, a carbobicyclic compound, a 3-hydroxy carboxylic acid and a statin (semi-synthetic). It is functionally related to a (S)-2-methylbutyric acid and a (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. It is a conjugate acid of a pravastatin(1-).", "chebi": "A carboxylic ester resulting from the formal condensation of (<i>S</i>)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3<i>R</i>,5<i>R</i>)-7-[(1<i>S</i>,2<i>S</i>,6<i>S</i>,8<i>S</i>,8a<i>R</i>)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.", "chembl": "PRAVASTATIN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Pravastatin, sold under the brand name Pravachol among others, is a statin medication, used for preventing cardiovascular disease in those at high risk and treating abnormal lipids. It is suggested to be used together with diet changes, exercise, and weight loss. It is taken by mouth.\nCommon side effects include joint pain, diarrhea, nausea, headaches, and muscle pains. Serious side effects may include rhabdomyolysis, liver problems, and diabetes. Use during pregnancy may harm the fetus. Like all statins, pravastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver that plays a role in producing cholesterol.\nPravastatin was patented in 1980 and approved for medical use in 1989. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 57th most commonly prescribed medication in the United States, with more than 11 million prescriptions."}